InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,832.00
(
-1.00%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.23
(
-0.38%
)
Bitcoin
64,298.46
(
-3.18%
)
Post# of 61
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

RealGenius

Send PM Follow Ignore
Followers 91
Posts 1956
Boards Moderated 0
Alias Born 07/31/2013

RealGenius

Re: None

Sunday, 03/01/2015 2:02:46 AM

Sunday, March 01, 2015 2:02:46 AM

Post# of 61
Financial: In 2015, the Company expects to continue receiving revenue from Selincro royalties from Lundbeck and a limited contribution towards certain tozadenant development costs from UCB. Research and development expenses on all development products are expected to increase, predominantly due to the start of the tozadenant Phase 3 study.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up